LivaNova PLC (LIVN) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $80.00 (+0.38%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 25, 2026 | Mike Matson | Needham | $81.00 | +1.2% |
| Feb 19, 2026 | Adam Maeder | Piper Sandler | $85.00 | +6.2% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $66.00 | -17.5% |
| Dec 19, 2025 | Brett Fishbin | KeyBanc | $81.00 | +1.2% |
| Dec 17, 2025 | Anthony Petrone | Mizuho Securities | $72.00 | -10.0% |
| Oct 31, 2024 | Anthony Petrone | Mizuho Securities | $70.00 | -12.5% |
| Oct 4, 2024 | David Roman | Goldman Sachs | $65.00 | -18.8% |
| Sep 17, 2024 | David Rescott | Robert W. Baird | $66.00 | -17.5% |
| Jul 25, 2024 | Rick Wise | Stifel Nicolaus | $72.00 | -10.0% |
| Jun 6, 2024 | Rick Wise | Stifel Nicolaus | $70.00 | -12.5% |
| Mar 20, 2024 | Rick Wise | Stifel Nicolaus | $65.00 | -18.8% |
Top Analysts Covering LIVN
LIVN vs Sector & Market
| Metric | LIVN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.38 | 2.24 | 2.41 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | -0.6% | +11475.0% | +17.1% |
| P/E Ratio | 40.46 | 3.99 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $379M | $380M | $380M | 5 |
| 2026-09-30 | $380M | $381M | $383M | 2 |
| 2026-12-31 | $387M | $388M | $389M | 2 |
| 2027-03-31 | $367M | $368M | $369M | 2 |
| 2027-06-30 | $403M | $404M | $406M | 2 |
| 2027-09-30 | $405M | $406M | $407M | 2 |
| 2027-12-31 | $413M | $414M | $415M | 2 |
| 2028-12-31 | $1.72B | $1.74B | $1.77B | 4 |
| 2029-12-31 | $1.69B | $1.75B | $1.78B | 3 |
| 2030-12-31 | $1.80B | $1.86B | $1.89B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.07 | $1.09 | $1.11 | 6 |
| 2026-09-30 | $1.13 | $1.13 | $1.14 | 3 |
| 2026-12-31 | $1.09 | $1.09 | $1.09 | 4 |
| 2027-03-31 | $1.03 | $1.03 | $1.04 | 2 |
| 2027-06-30 | $1.20 | $1.21 | $1.21 | 2 |
| 2027-09-30 | $1.20 | $1.20 | $1.21 | 2 |
| 2027-12-31 | $1.14 | $1.15 | $1.15 | 2 |
| 2028-12-31 | $4.59 | $5.05 | $5.50 | 2 |
| 2029-12-31 | $5.57 | $5.81 | $5.92 | 1 |
| 2030-12-31 | $6.14 | $6.41 | $6.53 | 1 |
Frequently Asked Questions
What is the analyst consensus for LIVN?
The consensus among 8 analysts covering LivaNova PLC (LIVN) is Buy with an average price target of $75.88.
What is the highest price target for LIVN?
The highest price target for LIVN is $85.00, set by Adam Maeder at Piper Sandler on 2026-02-19.
What is the lowest price target for LIVN?
The lowest price target for LIVN is $65.00, set by Rick Wise at Stifel Nicolaus on 2024-03-20.
How many analysts cover LIVN?
8 analysts have issued ratings for LivaNova PLC in the past 12 months.
Is LIVN a buy or sell right now?
Based on 8 analyst ratings, LIVN has a consensus rating of Buy (2.38/5) with a -0.6% upside to the consensus target of $75.88.
What are the earnings estimates for LIVN?
Analysts estimate LIVN will report EPS of $1.09 for the period ending 2026-06-30, with revenue estimated at $380M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.